Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction.


Journal Article

BACKGROUND: Nitrates are commonly prescribed to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. We compared the effect of isosorbide mononitrate or placebo on daily activity in such patients. METHODS: In this multicenter, double-blind, crossover study, 110 patients with heart failure and a preserved ejection fraction were randomly assigned to a 6-week dose-escalation regimen of isosorbide mononitrate (from 30 mg to 60 mg to 120 mg once daily) or placebo, with subsequent crossover to the other group for 6 weeks. The primary end point was the daily activity level, quantified as the average daily accelerometer units during the 120-mg phase, as assessed by patient-worn accelerometers. Secondary end points included hours of activity per day during the 120-mg phase, daily accelerometer units during all three dose regimens, quality-of-life scores, 6-minute walk distance, and levels of N-terminal pro-brain natriuretic peptide (NT-proBNP). RESULTS: In the group receiving the 120-mg dose of isosorbide mononitrate, as compared with the placebo group, there was a nonsignificant trend toward lower daily activity (-381 accelerometer units; 95% confidence interval [CI], -780 to 17; P=0.06) and a significant decrease in hours of activity per day (-0.30 hours; 95% CI, -0.55 to -0.05; P=0.02). During all dose regimens, activity in the isosorbide mononitrate group was lower than that in the placebo group (-439 accelerometer units; 95% CI, -792 to -86; P=0.02). Activity levels decreased progressively and significantly with increased doses of isosorbide mononitrate (but not placebo). There were no significant between-group differences in the 6-minute walk distance, quality-of-life scores, or NT-proBNP levels. CONCLUSIONS: Patients with heart failure and a preserved ejection fraction who received isosorbide mononitrate were less active and did not have better quality of life or submaximal exercise capacity than did patients who received placebo. (Funded by the National Heart, Lung, and Blood Institute; number, NCT02053493.).

Full Text

Duke Authors

Cited Authors

  • Redfield, MM; Anstrom, KJ; Levine, JA; Koepp, GA; Borlaug, BA; Chen, HH; LeWinter, MM; Joseph, SM; Shah, SJ; Semigran, MJ; Felker, GM; Cole, RT; Reeves, GR; Tedford, RJ; Tang, WHW; McNulty, SE; Velazquez, EJ; Shah, MR; Braunwald, E; NHLBI Heart Failure Clinical Research Network,

Published Date

  • December 10, 2015

Published In

Volume / Issue

  • 373 / 24

Start / End Page

  • 2314 - 2324

PubMed ID

  • 26549714

Pubmed Central ID

  • 26549714

Electronic International Standard Serial Number (EISSN)

  • 1533-4406

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1510774


  • eng

Conference Location

  • United States